Seattle Medical Marijuana Association
We are open 10am-10pm Sunday-Thursday and 10am-11pm on Friday and Saturday
Seattle Medical Marijuana is now accepting new patients! Our goal is to provide Seattle medical marijuana patients safe access to the highest quality medicine available.
Seattle Medical Marijuana Association is dedicated to serving those in need as defined by Chapter 69.51a RCW. Our Doctors section has information on where to schedule an appointment to obtain your authorization.
We offer our members access to a wide range of 100% organically grown medicine. We offer free consultations from our expert staff as well.
Seattle Medical Marijuana is here to help.
"SMMA is a not for profit small grow co-op of legal Washington State Medical Marijuana patients and providers. Our goal is to create a safe and legal resource for patients and providers."
Seattle Medical Marijuana Association is a small grow co-op consisting of qualified marijuana patients linked together by their mutual need to produce the highest quality organic medicine for personal use. It is explicitly designed to conform with Washington State laws protecting qualified patients from prosecution for possession of medical marijuana. We strive to provide a safe place for patients that is a model of compassion and legal integrity. The SMMA operates in strict compliance with the letter and the spirit of Washington's medical marijuana laws.
As distribution of cannabis remains illegal, cultivation is the only method by which cannabis may be obtained under state law. While not specifically sanctioned under RCW: 69.51A, collective cultivation is also not denied. Due to the costly high-tech equipment and resources required for indoor cultivation of medical cannabis, the majority of patients are unable to grow their own medicine. Thus, collective cultivation has become the only viable legal option for most patients. We provide a comfortable location with safe access to a wide variety of medication including dried marijuana, edibles, extracts, and concentrates.
Lifelong Aids Alliance
Crohn's and Colitis Foundation of America
Susan G Komen for the cure
News and Events
Appropriate Supply for Proper MMJ Dosing In WA
In Washington State it is more important than ever that we responsibly address the question of what “could reasonably be presumed to be a sixty-day supply for qualifying patients?” It should be obvious that defining a 60-day supply is equivalent to defining a 1-day supply and multiplying that figure by 60. It is also roughly equivalent to defining a 1-week supply and multiplying that figure by 8 or dividing an annual supply by 6.
Let us begin with some basic definitions. According to state law, “Medical use of ‘marijuana’ means the production, possession, or administration of marijuana, as defined in RCW 69.50.101(q), for the exclusive benefit of a qualifying patient in the treatment of his or her terminal or debilitating illness” (RCW 69.51A.010, Section 1, emphasis added). In this definition, the concept that is most relevant to the question at hand is the administration of marijuana. This is a technical concept defined in law. The relevant statute cited is RCW 69.50.101(q). The definition there for our purposes is as follows: “Administer” means to apply a controlled substance, whether by injection, inhalation, ingestion, or any other means, directly to the body of a patient...by the patient." Thus, the “medical use of marijuana” means the administration of a supply of marijuana directly to the body of a qualifying patient by the patient. Route of administration is an important determinant of the pharmacokinetics of the various cannabinoids in cannabis, particularly absorption and metabolism. Typically, cannabis is smoked, which has the advantage of rapid onset of effect and easy dose titration. Due to their volatility, cannabinoids will vaporize at a much lower temperature than combustion, allowing them to be inhaled as a warm air mist.\ This is a much healthier option than smoking. However, there may be differing vaporization points for the individual cannabinoids. Thus, vaporized cannabis may have differing concentrations and ratios of cannabinoids compared with smoked cannabis. Cannabinoids in the form of an aerosol in inhaled smoke or vapors are absorbed and delivered to the brain and circulation rapidly, as expected of a highly lipid-soluble drug. With smoking, up to 40% of the available cannabinoids may be completely combusted or lost sin sidestream smoke and thus be biologically unavailable. Cannabis may also be ingested orally, but this delivery route has markedly different pharmacokinetics compared with inhalation. The onset of action is delayed and titration of dosing is more difficult. Maximum cannabinoid blood levels are only reached up to 6 hours post ingestion, with a much longer half-life, as long as 20–30 hours. This would apply to dronabinol (Marinol), the pharmacokinetics of which were used as the foundation of our original dosing guidelines. With respect to dronabinol, which is 100% pure, synthetic delta-9 tetrahydrocannabinol (THC), this is converted in the liver to 11-hydroxy-THC, a potent psychoactive agent. This metabolite accounts for the considerable sedation that patients often experience with dronabinol. Despite the persistent warnings from the Drug Enforcement Agency (DEA) that “today's marijuana is stronger,” both the US Food and Drug Administration (FDA) and the DEA agreed to reclassify the scheduling status of dronabinol from a Schedule II (CII) to a Schedule III (CIII) controlled substance, due to its remarkable safety profile (which is inherent to all cannabinoids). The cannabinoids may also be made in to a liniment and absorbed through the skin. This was a common treatment for arthritis around the turn of 20th century. However, this is the least efficient mode of delivery.
The WA DOH must be aware of these common modes of administration and establish a 60-day supply that presumes that any and all of these common methods of administration of medical marijuana are being employed by qualifying patients. Given the inherent variations in strain and phenotype of cannabis, the various routes of administration employed, and the multitude of debilitating or terminal conditions being treated in patients using medicinal cannabis, standards must be set that maximize the potential for symptomatic relief. To do anything less would be unethical. Minimally, this implies setting standards with respect to the use of the least potent strains of marijuana and the most amount-intensive routes of administration.
The logical place to begin with regard to addressing the question of what constitutes a medically reasonable supply range is to investigate current dosing/supply precedents in American cannabinoid medicine. First and foremost, the WA DOH should draw from the experience of the longest running medical marijuana supply program in the United States, this being the ongoing, now 3-decades-old, Compassionate Single Investigational New Drug Program. The National Institute on Drug Abuse (NIDA) and the FDA jointly administer this. This program has supplied enrolled patients with nearly half a ton of marijuana throughout its cumulative history! The cannabis plants are grown at a federally funded farm in Oxford, Mississippi. After curing (air-drying), the cannabis is rolled into cigarettes at the Research Triangle Institute outside of Durham, North Carolina. Grey metal tins are used to package the cannabis cigarettes, which are then shipped monthly to 5 secured pharmacies in the United States for delivery and consumption by the 5 individuals whose healthcare providers long ago attested in writing to the vital health and medical benefits that consumption of cannabis affords them. The director of the Mississippi farm has stated on the public record that they have been able to produce, stock, and supply medicinal cannabis with strengths as high as 14% THC. The marijuana is produced and supplied for consumption with the full financial backing and imprimatur of the US federal government, the NIDA, and the FDA, as part of a program that was reluctantly started 3 decades ago on the order of a federal judge who ruled that “medical necessity” to use marijuana was an unalienable right possessed by one man whose vision was deteriorating from glaucoma, and which the US government is legally obligated to respect, protect, and fulfill.
Sunil K. Aggarwal, a prominent resident physician at a NY medical college can attest to personally meeting with the horticulturalist who has been growing medical marijuana for the federal government's marijuana supply program for nearly 3 decades, Dr. Mahmood El Sohly. In addition, he has met with 3 of the qualifying patients in the program who have chosen to go public: George McMahon, who suffers from nail-patella syndrome; Irv Rosenfeld, who suffers from multiple congenital cartilaginous exostoses; and Elvy Musikka, who suffers from congenital cataracts and glaucoma. Russo and colleagues summarized the supply that 4 of the 5 remaining patients in the program are receiving. On the basis of those reported figures, Conrad summarized the average supply for each patient in the federal program, assuming roughly equal strain strength. According to Conrad, the annual dose is between 5.6 and 7.23 lb of cannabis bud mixed with leaf. Thus, the documented federal single-patient dosage averages 8.24 g/day, or about one fourth ounce per day, which amounts to 6.63 lb smoked per year.
Thus, following the federal guidelines, an average of 6.63 lb of smoked medical marijuana, per patient per year, translates to a 60-day supply of 1.105 lb (assuming six 60-day periods per year) per patient. We emphasize here that this calculation is for administration of herbal cannabis through combustion-driven lung absorption only because this is the sole method of administration considered in the federal program, as the marijuana is delivered prerolled into cigarettes for smoking. In order to administer an equivalent amount of marijuana through gut absorption, an estimated 3–5 times greater quantity of marijuana is required, assuming equal efficiency and loss in both processes. Validation of this conversion factor comes from dose considerations elucidated by Dr. Reese Jones, MD, a professor of psychiatry at the University of California, San Francisco, School of Medicine. In a published federal document, submitted on record, to Congress, Dr. Jones opined: “THC has been estimated to be 3 to 5 times more potent when inhaled than when ingested.” He then gave a concrete example: “A marijuana cigarette containing 2 percent THC would deliver slightly less than 10 milligrams of THC to the lungs where must [sic] is probably absorbed. But to reach an equivalent state of intoxication when taken orally, from 30 to 50 milligrams of THC would have to be consumed.” We can use this same conversion factor, even though we are interested in medically desired endpoints. Applying an average multiplication factor of 4 (which is between 3 and 5) would mean that if the federal medical marijuana patients received a supply of marijuana intended for gut absorption in order to achieve pharmacologically equivalent blood levels as achieved through combustion and inhalation, an annual supply of 6.63 lb x 4 = 26.52 lb per patient would be required. Dividing by 6, this translates to a 60-day supply of (26.52 lb/6 =) 4.42 lb or 70.72 oz per patient.
In our previous study, we (GTC and MKT) used a different method to estimate a 60-day supply. In that study, we based our supply recommendations on the dosing regimen of dronabinol, a soft gelatin-encapsulated, synthetic THC isomer dissolved in sesame seed oil. This has been sold since 1985, with FDA approval, under the trade name Marinol. We took the very conservative dronabinol dosing model and applied it to standard combustion-and-inhalation pharmacokinetics for cannabis. Applying this to the least potent strains, we derived a 60-day cannabis supply of 15.7 oz, which is essentially 1 lb. This is strikingly similar to the 1.105 lb of smoked marijuana as calculated above. Applying our gut delivery 4-fold conversion factor, this translates to a 60-day supply of 62.8 oz or 3.925 lb.
It is crucial during these times of change and diminishing patient rights we fight to ensure appropriate access to necessary quantities for people in WA that truly need this healing herb to find and maintain a healthy, comfortable and balanced life.